Results 141 to 150 of about 18,916,175 (220)

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim   +37 more
wiley   +1 more source

A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials. [PDF]

open access: yesFuture Oncol
Leger P   +8 more
europepmc   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng   +7 more
wiley   +1 more source

Re‐evaluating variability of circulating miR‐122 in healthy volunteers: Implications for biomarker qualification in drug‐induced liver injury

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Drug‐induced liver injury (DILI) remains a major challenge in clinical practice and drug development, and reliable biomarkers are still needed. MicroRNA‐122 (miR‐122) has shown promise, but reported inter‐individual variability in healthy populations has raised concerns about its clinical utility.
Irum Javid   +12 more
wiley   +1 more source

Gene expression-based modeling of overall survival in Black or African American patients with lung adenocarcinoma. [PDF]

open access: yesFront Immunol
Zhu B   +7 more
europepmc   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor   +11 more
wiley   +1 more source

Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions ...
Jianfeng Xu   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy